Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma.
Cardiotoxicity is a well-known consequence of anthracycline chemotherapy. We report CMR findings not previously described in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma. Subendocardial enhancement on late gadolinium contrast-enhanced CMR was present in both cases, with histological correlation in one case.
Perel
Robert D
RD
Cardiovascular MRI Research Centre, The Prince Charles Hospital, Brisbane, Australia.
Slaughter
Richard E
RE
Strugnell
Wendy E
WE
D000328:Adult; D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D007089:Image Enhancement; D019028:Magnetic Resonance Imaging, Cine; D008297:Male; D009206:Myocardium / Q000473:pathology*; D012512:Sarcoma, Ewing / Q000188:drug therapy
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D003287:Contrast Media; D019786:Gadolinium DTPA